Integrase-defective lentiviral vectors: Progress and applications

Gene Therapy

Volumn 17, Issue 2, 2010, Pages 150-157

  Banasik, M B ^a   McCray, P B ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Episome; FIV; HIV; Vaccine; Zinc finger nuclease

Indexed keywords

DOUBLE STRANDED DNA; INTEGRASE; INTEGRATION DEFECTIVE LENTIVIRUS VECTOR; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VACCINE;

CELL NUCLEUS TRANSPLANTATION; CPG ISLAND; DNA BINDING; DNA FLANKING REGION; DNA INTEGRATION; ENZYME ACTIVITY; EPISOME; GENE CASSETTE; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE TARGETING; GENE TRANSLOCATION; GENETIC TRANSDUCTION; HETEROZYGOSITY; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOPROPHYLAXIS; INTERNALIZATION; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVERSE TRANSCRIPTION; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS DNA CELL DNA INTERACTION; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

ANIMALS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INTEGRASES; LENTIVIRUS; MUTAGENESIS, INSERTIONAL; TRANSGENES; VIRUS INTEGRATION;

FELINE IMMUNODEFICIENCY VIRUS;

EID: 76749152709     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.135     Document Type: Review

References (87)

1. Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 2001; 12: 1893-1905.
2. Sinn PL, Sauter SL, McCray Jr PB. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Therapy 2005; 12: 1089-1098.
3. Leavitt AD, Shiue L, Varmus HE. Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro. J Biol Chem 1993; 268: 2113-2119.
4. Leavitt AD, Robles G, Alesandro N, Varmus HE. Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol 1996; 70: 721-728.
5. Shibagaki Y, Holmes ML, Appa RS, Chow SA. Characterization of feline immunodeficiency virus integrase and analysis of functional domains. Virology 1997; 230: 1-10.
6. Shibagaki Y, Chow SA. Central core domain of retroviral integrase is responsible for target site selection. J Biol Chem 1997; 272: 8361-8369.
7. Talbott RL, Sparger EE, Lovelace KM, Fitch WM, Pedersen NC, Luciw PA et al. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci USA 1989; 86: 5743-5747.
8. Nisole S, Saib A. Early steps of retrovirus replicative cycle. Retrovirology 2004; 1: 9.
9. Craigie R, Fujiwara T, Bushman F. The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. Cell 1990; 62: 829-837.
10. Katz RA, Merkel G, Kulkosky J, Leis J, Skalka AM. The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro. Cell 1990; 63: 87-95.
11. Katz RA, Skalka AM. The retroviral enzymes. Annu Rev Biochem 1994; 63: 133-173.
12. Engelman A, Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol 1992; 66: 6361-6369.
13. Nightingale SJ, Hollis RP, Pepper KA, Petersen D, Yu XJ, Yang C et al. Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 2006; 13: 1121-1132.
14. Mizuuchi K. Polynucleotidyl transfer reactions in transpositional DNA recombination. J Biol Chem 1992; 267: 21273-21276.
15. Goff SP. Retroviridae: the retroviruses and their replication. In: David M Knipe PMH, Diane E Griffin, Malcolm A Martin, Robert A Lamb, Bernard Roizman, Stephen E Strauss (ed). Fields Virology, 4th edn, vol.2. Lippincott Williams & Wilkins: Philadelphia, 2001. pp 1871-1940.
16. Yoder KE, Bushman FD. Repair of gaps in retroviral DNA integration intermediates. J Virol 2000; 74: 11191-11200.
17. Farnet CM, Haseltine WA. Circularization of human immunodeficiency virus type 1 DNA in vitro. J Virol 1991; 65: 6942-6952.
18. Pauza CD, Trivedi P, McKechnie TS, Richman DD, Graziano FM. 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. Virology 1994; 205: 470-478.
19. Pages JC, Bru T. Toolbox for retrovectorologists. J Gene Med 2004; 6 (Suppl 1): S67-S82.
20. Miller MD, Wang B, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes containing discontinuous plus strands are competent to integrate in vitro. J Virol 1995; 69: 3938-3944.
21. Li L, Olvera JM, Yoder KE, Mitchell RS, Butler SL, Lieber M et al. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J 2001; 20: 3272-3281.
22. Bayer M, Kantor B, Cockrell A, Ma H, Zeithaml B, Li X et al. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol Ther 2008; 16: 1968-1976.
23. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002; 76: 3739-3747.
24. Nandi JS. Unintegrated viral DNA as a marker for human immunodeficiency virus 1 infection in vivo and in vitro. Acta Virol 1999; 43: 367-372.
25. Brussel A, Sonigo P. Evidence for gene expression by unintegrated human immunodeficiency virus type 1 DNA species. J Virol 2004; 78: 11263-11271.
26. Stevenson M, Haggerty S, Lamonica CA, Meier CM, Welch SK, Wasiak AJ. Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J Virol 1990; 64: 2421-2425.
27. Shoemaker C, Hoffman J, Goff SP, Baltimore D. Intramolecular integration within Moloney murine leukemia virus DNA. J Virol 1981; 40: 164-172.
28. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002; 76: 4138-4144.
29. Barquinero J, Eixarch H, Perez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Therapy 2004; 11(Suppl 1): S3-S9.
30. Baum C, Schambach A, Bohne J, Galla M. Retrovirus vectors: toward the plentivirus? Mol Ther 2006; 13: 1050-1063.
31. Rodrigues T, Carrondo MJ, Alves PM, Cruz PE. Purification of retroviral vectors for clinical application: biological implications and technological challenges. J Biotechnol 2007; 127: 520-541.
32. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300: 1749-1751.
33. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
34. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
35. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193. (Pubitemid 34984579)
36. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-3150.
37. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132-3142.
38. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004; 2: E234.
39. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002; 110: 521-529.
40. Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD. HIV integration site selection: analysis by massively parallel pyrose-quencing reveals association with epigenetic modifications. Genome Res 2007; 17: 1186-1194.
41. Kang Y, Moressi CJ, Scheetz TE, Xie L, Tran DT, Casavant TL et al. Integration site choice of a feline immunodeficiency virus vector. J Virol 2006; 80: 8820-8823.
42. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119: 964-975.
43. Metais JY, Dunbar CE. The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. Mol Ther 2008; 16: 439-449.
44. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298-1306.
45. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, Eichtinger M et al. Rapid 'open-source' engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 2008; 31: 294-301.
46. Yu SS, Dan K, Chono H, Chatani E, Mineno J, Kato I. Transient gene expression mediated by integrase-defective retroviral vectors. Biochem Biophys Res Commun 2008; 368: 942-947.
47. Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, Petit C et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 2006; 103: 17684-17689.
48. Saenz DT, Loewen N, Peretz M, Whitwam T, Barraza R, Howell KG et al. Unintegrated lentivirus DNA persistence and accessi-bility to expression in nondividing cells: analysis with class I integrase mutants. J Virol 2004; 78: 2906-2920.
49. Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006; 12: 348-353.
50. Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 2007; 15: 1947-1954.
51. Cornu TI, Cathomen T. Targeted genome modifications using integrase-deficient lentiviral vectors. Mol Ther 2007; 15: 2107-2113.
52. Coutant F, Frenkiel MP, Despres P, Charneau P. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 2008; 3: e3973.
53. Moldt B, Staunstrup NH, Jakobsen M, Yanez-Munoz RJ, Mikkelsen JG. Genomic insertion of lentiviral DNA circles directed by the yeast Flp recombinase. BMC Biotechnol 2008; 8: 60.
54. Negri DR, Michelini Z, Baroncelli S, Spada M, Vendetti S, Buffa V et al. Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 2007; 15: 1716-1723.
55. Okada Y, Ueshin Y, Hasuwa H, Takumi K, Okabe M, Ikawa M. Targeted gene modification in mouse ES cells using integrase-defective lentiviral vectors. Genesis 2009; 47: 217-223.
56. Rahim AA, Wong AM, Howe SJ, Buckley SM, Acosta-Saltos AD, Elston KE et al. Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Therapy 2009; 16: 509-520.
57. Staunstrup NH, Moldt B, Mates L, Villesen P, Jakobsen M, Ivics Z et al. Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol Ther 2009; 17: 1505-1514.
58. Vargas Jr J, Gusella GL, Najfeld V, Klotman ME, Cara A. Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 2004; 15: 361-372.
59. Vargas Jr J, Klotman ME, Cara A. Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy. Antiviral Res 2008; 80: 288-294.
60. Vink CA, Gaspar HB, Gabriel R, Schmidt M, McIvor RS, Thrasher AJ et al. Sleeping beauty transposition from noninte-grating lentivirus. Mol Ther 2009; 17: 1197-1204.
61. Loewen N, Leske DA, Chen Y, Teo WL, Saenz DT, Peretz M et al. Comparison of wild-type and class I integrase mutant-FIV vectors in retina demonstrates sustained expression of integrated transgenes in retinal pigment epithelium. J Gene Med 2003; 5: 1009-1017.
62. van Gent DC, Oude Groeneger AA, Plasterk RH. Identification of amino acids in HIV-2 integrase involved in site-specific hydrolysis and alcoholysis of viral DNA termini. Nucleic Acids Res 1993; 21: 3373-3377.
63. Khan E, Mack JP, Katz RA, Kulkosky J, Skalka AM. Retroviral integrase domains: DNA binding and the recognition of LTR sequences. Nucleic Acids Res 1991; 19: 851-860.
64. Ellison V, Brown PO. A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro. Proc Natl Acad Sci USA 1994; 91: 7316-7320.
65. Engelman A, Bushman FD, Craigie R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J 1993; 12: 3269-3275.
66. Ellison V, Gerton J, Vincent KA, Brown PO. An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer. J Biol Chem 1995; 270: 3320-3326.
67. Craigie R. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem 2001; 276: 23213-23216.
68. Lu R, Limon A, Ghory HZ, Engelman A. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J Virol 2005; 79: 2493-2505. (Pubitemid 40204604)
69. Engelman A, Hickman AB, Craigie R. The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding. J Virol 1994; 68: 5911-5917.
70. Kulkosky J, Jones KS, Katz RA, Mack JP, Skalka AM. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol 1992; 12: 2331-2338.
71. Drelich M, Wilhelm R, Mous J. Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in vitro. Virology 1992; 188: 459-468.
72. Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 1995; 69: 376-386.
73. Lutzke RA, Plasterk RH. Structure-based mutational analysis of the C-terminal DNA-binding domain of human immunodeficiency virus type 1 integrase: critical residues for protein oligomerization and DNA binding. J Virol 1998; 72: 4841-4848.
74. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
75. Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96: 1173-1176.
76. Wu Y. HIV-1 gene expression: lessons from provirus and non-integrated DNA. Retrovirology 2004; 1: 13.
77. Nakajima N, Lu R, Engelman A. Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines. J Virol 2001; 75: 7944-7955.
78. Gaur M, Leavitt AD. Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not eliminate provirus formation. J Virol 1998; 72: 4678-4685.
79. Lim JK, Glass WG, McDermott DH, Murphy PM. CCR5: no longer a 'good for nothing' gene-chemokine control of West Nile virus infection. Trends Immunol 2006; 27: 308-312.
80. Lombardo A, Cesana D, Genovese P, Provasi E, Maruggi G, Binini C et al. Characterization of potential genomic 'safe harbor' for efficient targeted gene addition with zinc finger nucleases. Mol Ther 2009; 17: S168.
81. Mairhofer J, Grabherr R. Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA. Mol Biotechnol 2008; 39: 97-104.
82. Chen ZY, He CY, Meuse L, Kay MA. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Therapy 2004; 11: 856-864.
83. Mayrhofer P, Blaesen M, Schleef M, Jechlinger W. Minicircle-DNA production by site specific recombination and protein-DNA interaction chromatography. J Gene Med 2008; 10: 1253-1269.
84. Davidson BL, Boudreau RL. RNA interference: a tool for querying nervous system function and an emerging therapy. Neuron 2007; 53: 781-788.
85. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004; 101: 8676-8681.
86. Snove Jr O, Rossi JJ. Expressing short hairpin RNAs in vivo. Nat Methods 2006; 3: 689-695.
87. Scherr M, Eder M. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 2007; 6: 444-449.